Financial Performance - In 2023, the company reported operating revenue of CNY 242,799,574.73, a decrease of 9.89% compared to the previous year[2] - The net profit attributable to shareholders was CNY 18,238,455.70, down 45.82% year-on-year[2] - The net profit after deducting non-recurring gains and losses was CNY 14,232,236.04, a decline of 54.89% compared to the previous year[2] - The basic earnings per share decreased to CNY 0.24, down 57.89% year-on-year[2] Assets and Investments - Total assets at the end of the reporting period were CNY 448,229,584.83, an increase of 1.76% from the beginning of the year[3] Future Plans and Projects - The company plans to complete the "Technological Transformation and Capacity Expansion Project (Phase I)" by mid-2024, aiming to enhance production efficiency through automation and digitalization[4] - The U.S. subsidiary's establishment is nearly complete, with plans to strengthen market expansion in the U.S. in 2024[5] - The company aims to enhance its competitive edge through product development and expand both domestic and international markets in 2024[5] Product Development - The product "Diosmin" has passed GMP compliance checks and is expected to be sold in the domestic market in 2024[5] - The company obtained 8 food production licenses in 2023, allowing for further development in the domestic food raw material market in 2024[5]
欧康医药(833230) - 2023 Q4 - 年度业绩